Inmune Bio (INMB) Free Cash Flow (2018 - 2026)
Inmune Bio (INMB) posted Free Cash Flow of -$3.4 million for Q1 2026, down 8.27% sequentially from -$3.1 million in Q4 2025, and up 50.13% YoY from -$2.3 million in Q1 2025.
Inmune Bio (INMB) Free Cash Flow (2018 - 2026) Analysis & Trends
Inmune Bio has reported Free Cash Flow for 9 years, with the latest figure at -$3.4 million in Q1 2026.
- Quarterly Free Cash Flow rose 50.13% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.5 million (up 40.41% YoY) and the FY2025 annual result came in at -$23.6 million, up 29.22% from the prior year.
- Free Cash Flow slipped to -$3.4 million in Q1 2026 per INMB's latest filing, from -$3.1 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$1.1 million in Q1 2023 and troughed at -$11.1 million in Q4 2024.
- A 5-year average of -$5.6 million and a median of -$5.6 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow soared 87.13% in 2023, then plunged 555.21% in 2024.
- Over 5 years, Free Cash Flow stood at -$5.7 million in 2022, then soared by 39.93% to -$3.4 million in 2023, then sank by 223.06% to -$11.1 million in 2024, then surged by 71.56% to -$3.1 million in 2025, then decreased by 8.27% to -$3.4 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$3.4 million, -$3.1 million, and -$5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | -3.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.20 Mn |
| Jun 30, 2026 | -3.20 Mn |
| Mar 31, 2026 | -3.40 Mn |
| Mar 31, 2026 | -3.40 Mn |
| Dec 31, 2025 | -3.14 Mn |
| Dec 31, 2025 | -3.14 Mn |
| Sep 30, 2025 | -5.59 Mn |
| Sep 30, 2025 | -5.59 Mn |
| Jun 30, 2025 | -7.38 Mn |
| Jun 30, 2025 | -7.38 Mn |
| Mar 31, 2025 | -6.82 Mn |
| Mar 31, 2025 | -6.82 Mn |
| Dec 31, 2024 | -11.05 Mn |
| Dec 31, 2024 | -11.05 Mn |
| Sep 30, 2024 | -6.99 Mn |
| Sep 30, 2024 | -6.99 Mn |
| Jun 30, 2024 | -7.89 Mn |
| Jun 30, 2024 | -7.89 Mn |
| Mar 31, 2024 | -7.48 Mn |
| Mar 31, 2024 | -7.48 Mn |